AR002953A1 - Purin-6-onas bisustituidas en 2,9, procedimiento para su produccion, medicamentos que las contienen y el uso de dichos compuestos para prepararmedicamentos. - Google Patents

Purin-6-onas bisustituidas en 2,9, procedimiento para su produccion, medicamentos que las contienen y el uso de dichos compuestos para prepararmedicamentos.

Info

Publication number
AR002953A1
AR002953A1 ARP960101088A AR10108896A AR002953A1 AR 002953 A1 AR002953 A1 AR 002953A1 AR P960101088 A ARP960101088 A AR P960101088A AR 10108896 A AR10108896 A AR 10108896A AR 002953 A1 AR002953 A1 AR 002953A1
Authority
AR
Argentina
Prior art keywords
medicines
purin
bisustituted
onas
compounds
Prior art date
Application number
ARP960101088A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR002953A1 publication Critical patent/AR002953A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se obtienen purin-6-onas bisustituidas en 2,9, acilando en una primera etapa los correspondientes amino-imidazoles sustituidos correspondientes yciclando, después de esto, para obtener la purina. Las nuevas purin-6-onas bisustituidas en 2,9pueden emplearse como sustancia activa en medicamentos,especialmente para el tratamiento de inflamaciones,enfermedades tromboembólicas y cardiovasculares y enfermedades del sistema urogenital.
ARP960101088A 1995-01-19 1996-01-19 Purin-6-onas bisustituidas en 2,9, procedimiento para su produccion, medicamentos que las contienen y el uso de dichos compuestos para prepararmedicamentos. AR002953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
AR002953A1 true AR002953A1 (es) 1998-05-27

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101088A AR002953A1 (es) 1995-01-19 1996-01-19 Purin-6-onas bisustituidas en 2,9, procedimiento para su produccion, medicamentos que las contienen y el uso de dichos compuestos para prepararmedicamentos.

Country Status (31)

Country Link
US (1) US5861404A (es)
EP (1) EP0722944A1 (es)
JP (1) JPH08231545A (es)
KR (1) KR960029334A (es)
CN (1) CN1135485A (es)
AR (1) AR002953A1 (es)
AU (1) AU4097996A (es)
BG (1) BG61728B1 (es)
BR (1) BR9600147A (es)
CA (1) CA2167353A1 (es)
CO (1) CO4700523A1 (es)
CZ (1) CZ16696A3 (es)
DE (1) DE19501482A1 (es)
EE (1) EE9600018A (es)
FI (1) FI960225A (es)
HR (1) HRP960007A2 (es)
HU (1) HUP9600106A3 (es)
IL (1) IL116769A (es)
MA (1) MA23778A1 (es)
NO (1) NO960223L (es)
NZ (1) NZ280830A (es)
PE (1) PE64996A1 (es)
PL (1) PL312354A1 (es)
SG (1) SG50401A1 (es)
SK (1) SK8096A3 (es)
SV (1) SV1996000006A (es)
TN (2) TNSN96006A1 (es)
TR (1) TR199600028A2 (es)
TW (1) TW314519B (es)
YU (1) YU1396A (es)
ZA (1) ZA96398B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6310070B1 (en) * 1997-07-15 2001-10-30 Japan Energy Corporation Purine derivatives and medicinal use thereof
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
CA2315736A1 (en) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
ATE254616T1 (de) * 1999-05-11 2003-12-15 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
EP1316316B1 (en) * 2000-09-06 2012-04-04 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
FI960225A (fi) 1996-07-20
HRP960007A2 (en) 1998-02-28
MA23778A1 (fr) 1996-10-01
EE9600018A (et) 1996-08-15
FI960225A0 (fi) 1996-01-17
SG50401A1 (en) 1998-07-20
YU1396A (sh) 1999-03-04
JPH08231545A (ja) 1996-09-10
BG100292A (bg) 1996-07-31
SV1996000006A (es) 1996-10-29
TNSN96006A1 (fr) 2005-03-15
AU4097996A (en) 1996-07-25
US5861404A (en) 1999-01-19
HUP9600106A3 (en) 1998-04-28
NZ280830A (en) 1998-04-27
SK8096A3 (en) 1996-08-07
CZ16696A3 (en) 1996-08-14
BR9600147A (pt) 1998-01-06
TNSN96007A1 (fr) 2005-03-15
IL116769A (en) 1998-12-06
CO4700523A1 (es) 1998-12-29
BG61728B1 (bg) 1998-04-30
DE19501482A1 (de) 1996-07-25
NO960223D0 (no) 1996-01-18
PL312354A1 (en) 1996-07-22
TW314519B (es) 1997-09-01
PE64996A1 (es) 1997-03-09
HUP9600106A2 (en) 1997-05-28
EP0722944A1 (de) 1996-07-24
KR960029334A (ko) 1996-08-17
ZA96398B (en) 1996-08-28
CN1135485A (zh) 1996-11-13
IL116769A0 (en) 1996-05-14
NO960223L (no) 1996-07-22
CA2167353A1 (en) 1996-07-20
TR199600028A2 (tr) 1996-08-21
HU9600106D0 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
AR002953A1 (es) Purin-6-onas bisustituidas en 2,9, procedimiento para su produccion, medicamentos que las contienen y el uso de dichos compuestos para prepararmedicamentos.
ES2052829T3 (es) Aminoetiltetralinas substituidas asi como sus analogos heterociclicos.
ES2147320T3 (es) Derivados de n-(3-benzofuranil)urea.
ES2038627T3 (es) Derivados del acido (met)-acrilico que contienen grupos uretano.
MX9201139A (es) Nuevos esteres de amino alcoholes bi- y triciclicos, procedimiento para su reparacion y composiciones farmaceuticas que los c0ntienen.
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
ES2147720T3 (es) Factor de celulas madre.
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
SE7707632L (sv) Forfarande for omvandling av cis-hexahydro-dibenso (b,d) pyran-9-oner till trans-hexahydro-dibenso (b,d) pyran-9-oner
IT1148801B (it) Derivati del nor-tropano, loro procedimento di preparazione e loro applicazione terapeutica
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
ES2046176T3 (es) Composicion farmaceutica que contiene una asociacion de colageno y de un principio activo antiseptico y/o antiinflamatorio y su procedimiento de fabricacion.
ES2155152T3 (es) Aminometilcromanos sustituidos por benzoisotiazolilo.
IT8021795A0 (it) Derivati del 5h-furanone-2 e del3h-diidrofuranone-2,loro procedimento di preparazione e loro applicazione terapeutica.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
ATE5188T1 (de) Phenylalkansaeure-derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IT7826593A0 (it) Derivati del 1,3-difenossipropano, processo per la loro preparazione e loro impiego come medicinali.
IT8747635A0 (it) Derivati della purina, loro preparazione e loro impiego come medicamenti
AR219296A1 (es) Alfa-aril-(trifluorcetil)-aminas utiles como intermediarios para preparar compuestos terapeuticos,y desprovistas de propiedades farmacologicas,y procedimiento para su obtencion
RO77527A (ro) Procedeu pentru obtinerea nitroetanului
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
ES2145284T3 (es) Derivados del acido dioxo-tiopirano-piridin-carboxilico y su uso como farmacos.
NO872671L (no) 4-benzyloksy-3-pyrrolin-2-on-1-yl-acetamid, fremstilling og anvendelse derav.
MX9303600A (es) Derivados de los acidos fenilpropionico y -cinamico sustituidos por imidazolilo, procedimiento para su obtencion y medicamentos que los contienen.